We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Non-Invasive Melanoma Test Ushers in New Era in Skin Cancer Detection

By LabMedica International staff writers
Posted on 25 Jan 2023

Skin cancer overall is the most common form of cancer with melanoma being the third most common and also the most aggressive form of skin cancer. More...

Now, an innovative test painlessly collect cells from the skin and applies precision genomics to diagnose melanoma accurately and at the earliest curable stage.

The DermTech Melanoma Test from DermTech (La Jolla, CA, USA) is a non-invasive genomic test that enables early detection of melanoma by identifying the presence of genomic markers found in melanoma – often much earlier than the current biopsy pathway. The Smart Sticker gently lifts skin cells containing genomic material from the surface of the skin while the adhesive on the sticker stores and preserves the skin cells so that it can be sent to DermTech’s Gene Lab for examination.

Using a proprietary precision genomic test, DermTech’s genomic analysis looks for melanoma at the gene level, 10,000 times closer than even a microscope. The test detects LINC00518 and PRAME using RT-PCR which makes billions of copies of these genes. An additional test can also be conducted to identify the presence of TERT gene driver mutations using a DNA sequencing technique. Positive results for LINC00518, PRAME, or TERT correlate with the presence of melanoma. If the genomic markers found in melanoma are present, this will typically result in a biopsy of the spot. If the biomarkers are not detected (meaning negative results), there could be a greater than 99% probability that the mole being tested is not melanoma.

The Smart Sticker uses a specially formulated adhesive to gently lift skin cells from the surface of the skin, but it is not strong enough to cause pain, bleeding or damage to the site. The DermTech Melanoma Test is not a replacement for a biopsy. If the genomic markers exist, then the doctor can use this information to choose the best path forward for the patient’s treatment. The DermTech Melanoma Test is rather a step before a biopsy that can see genomic markers linked to melanoma far earlier than the traditional biopsy pathway can.

Related Links:
DermTech


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Rapid Test Reader
DIA5000
New
Specimen Radiography System
TrueView 200 Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.